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Novel clinical features associated with Clouston
syndrome
Clouston syndrome (OMIM #129500), also known as hidrotic
ectodermal dysplasia type 2, is a rare autosomal dominant ecto-
dermal dysplasia.1–4 It is characterized by a triad of major fea-
tures that include partial to complete hair loss, severe nail
dystrophy, and palmoplantar hyperkeratosis with varying
degrees of severity.1–6 In affected individuals, the hair is pale,
fine, sparse, and grows very slowly, and total alopecia may
occur. The eyebrows and eyelashes are absent or sparse and
short. Nail abnormalities are characterized by thickened, ridged,
hyperconvex nails, and paronychia is frequently reported.3 The
teeth, sweat, and sebaceous glands are normal.1,2 Additional
clinical features include sensorineural deafness,5–7 hyperpig-
mentation of the skin over large joints,3,6 and eccrine syringofi-
broadenoma (Table 1).8
Heterozygous mutations in the gap junction beta 6 gene,
(GJB6, OMIM #604418), which encodes the gap junction pro-
tein connexin 30 (Cx30), result in Clouston syndrome.1,3 Four
heterozygous missense mutations (G11R, V37E, D50N, and
A88V) account for the majority of Clouston syndrome cases.1–3
Herein, we describe a Venezuelan child who presented with a
mild phenotype resulting from an A88V mutation, in GJB6, who
demonstrates novel clinical features associated with Clouston
syndrome expanding the phenotypic spectrum.
The patient was a 4-year-old Venezuelan boy, born from non-
consanguineous healthy parents (III:2), and the only affected
individual in the family (Fig. 1a). Dermatologic examination at
his first evaluation detected hair loss in the temporo-occipital
area (Fig. 1b) with sparse, pale, brittle hair on the scalp, abnor-
malities of the eyebrows and eyelashes (Fig. 1c), and slight
hypertrichosis on the posterior thorax (Fig. 1d). His fingernails
and toenails were dystrophic, short, whitened, and thickened
with distal wedge-shaped separation, associated with mild
paronychia (Fig. 1e,f). He had palmar hyperhidrosis without pal-
moplantar keratoderma (Fig. 1g). There was hyperpigmentation
in the periorbital region (Fig. 1c) and over the elbows and
knees. Sweating and teeth were normal. Ophthalmic examina-
tion at 9 years of age detected myopia and astigmatism. Audio-
logic testing revealed mild sensorineural hearing loss.
Targeted next generation sequencing detected a heterozygous
mutation c.263C>T (rs28937872) in the GJB6 gene
(NM_001110221.2) resulting in A88V (NP_001103691.1) non-
synonymous mutation (Fig. 2a). The mutation was confirmed by
Sanger sequencing in the proband, and sequencing of both par-
ents and the brother confirmed absence of this sequence vari-
ant, and hence this mutation arose de novo (Fig. 2b). A number
of bioinformatics modeling tools were employed to determine
the pathogeneicity of the A88V mutation and to predict the pos-
sible impact on the structure or function of Cx30 protein. Poly-
phen2 9 predicted the mutation as damaging (with a score of
0.984), and MutationTaster10 classified this variant as a dis-
ease-causing mutation. The conservation of the wild-type
nucleotide was assessed using PhastCons and PhyloP, and
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Present
case
Sex 2M/3F F F F 22M/15F 3M/2F M
Familiar case + + +  + + 
Alopecia    + 36/37 + 
Sparse hair + + +  1/37a  +
Nail dystrophy + + + + 34/37 + +
Palmar hyperkeratosis + + + + 21/37 + 
Plantar hyperkeratosis + + + + 24/37 + 
Photophobia NP NP + +b NP NP 
Sensorineural hearing
loss
NP  NP +b NP NP +c
Mental retardation  NP  NP NP NP 
Additional molecular
findings





aSlight clinical symptom that is difficult to diagnose.
bAssociated with the variant found in GJB2 gene.
cMild sensorineural hearing loss.
dTwo family members held a heterozygous missense mutation V37I in GJB2 gene.
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values of 0.991 and 5.988 were obtained, respectively. Values
close to 1 in PhastCons and +6 in PhyloP confirm high conser-
vation at this nucleotide, and the alanine at 88 position is highly
conserved through different species.
The c.263C>T (A88V) mutation in GJB6 was first identified in
two unrelated French families11 and was subsequently reported
in families from different ethnic populations.12 The alanine 88 is
conserved between human and mouse Cx30,4 and the introduc-
tion of a highly hydrophobic residue (valine, V), in the transmem-
brane M2 domain, would be expected to change the polarity of
connexin channels and intercellular communication11,13 or induce
Cx30 apoptosis through an endoplasmic reticulum-independent
mechanism.13
Clinical diagnosis in Clouston syndrome can be delayed in
the presence of phenotypic variability resulting in atypical clini-
cal presentation and milder symptoms in younger patients.3
Molecular genetic investigation is vital, especially in mild or
atypical cases, to provide diagnostic accuracy and understand
genotype-phenotype correlations.
Multidisciplinary follow-up is paramount to clinical care and
can provide control of treatable clinical features, emotional and




Figure 1 (a) Pedigree of the family, arrow indicates the proband (III:2), the only affected in the family with Clouston
syndrome, (b) hair loss in temporo-occipital area, (c) as well as eyebrows and eyelashes and hyperpigmentation in periorbital
region, (d) slight hypertrichosis in the posterior thorax, (e and f) fingernails and toenails are whitened, dystrophic, thickened
with distal wedge-shaped separation, (g) without palmoplantar keratoderma
International Journal of Dermatology 2019, 58, e143–e163 ª 2019 The International Society of Dermatology
Correspondencee144
keratoderma may develop during childhood and is more severe
in older patients.1,7 Treatment usually focuses on palmoplantar
keratoderma with emollients and keratolytic agents, special hair
care products, treatment of alopecia, ablation of the nail matrix,
and application of artificial nails.7
This study reports a sporadic case of Clouston syndrome in a
Venezuelan family molecularly confirmed. This case represents
the first case of Clouston syndrome described in Venezuela.
The clinical characteristics exhibited by the patient were mild
possibly because of the young age and characterized by the
absence of palmoplantar hyperkeratosis. However, this patient
presented hyperpigmentation in the periorbital region that can
produce an aspect of aging and slight localized hypertrichosis in
the posterior thorax in contrast with the typical findings found in
ectodermal dysplasia. This last finding was not associated with
the use of medication or any other entity that could justify it.
These are novel characteristics previously not reported in litera-
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Cutaneous hypereosinophilia secondary to a low-grade
B-cell lymphoma
Dear Editor,
Hypereosinophilic syndrome is a heterogeneous group of
disorders, commonly affecting the skin, characterized by abnor-
mal proliferation and accumulation of eosinophils causing end-
organ damage.1,2 If left untreated, hypereosinophilia is poten-
tially fatal, with a 10-year mortality of up to 50%.3
Clonal hypereosinophilia can be myeloproliferative or lym-
phoproliferative. Myeloproliferative hypereosinophilia is caused
by a molecular defect (most commonly the FIPIlI/PDGFRA
fusion gene) at the progenitor stem cell level of eosinophil differ-
entiation in the bone marrow, leading to clonal expansion of
eosinophils.4,5
Lymphoproliferative hypereosinophilia is usually associated
with abnormal T-cell clones which stimulate the production of
eosinophilopoietic cytokines including IL-4 and IL-5.
6 Hypere-
osinophilia associated with B-cell neoplasia is only occasionally
reported and tends to be in the context of B-cell non-Hodgkin’s
lymphoma.7
We describe an unusual case of cutaneous hypere-
osinophilia driven by a low-grade B-cell lymphoma, which was
successfully treated with rituximab.
A 58-year-old male presented with a 2-week history of a
generalized pruritic rash, on a background of night sweats, fati-
gue, and weight loss over the preceding 6 months. Clinical
examination revealed a bright red raised confluent rash from
head to toe, with sparing of the inframammary and periumbilical
region (Fig. 1). There was splenomegaly and generalized lym-
phadenopathy.
Laboratory investigations of peripheral blood demonstrated
an elevated white cell count 12.5 9 109/l (normal: 4–10), ele-
vated eosinophil count 7.6 9 109/l (normal: 0.02–0.5), raised
CRP 78 mg/l (normal: 0–5), and increased levels of IgE 744 kU/
l (normal: 0–100) and IgG 29.8 g/l (normal: 6.8–15.3). Serum
tryptase level was normal. Radiological investigation confirmed
splenomegaly and widespread lymphadenopathy. Skin biopsy
demonstrated an eosinophil-rich inflammation (Fig. 2). Infective
and autoimmune screens were negative.
Differential diagnosis included a drug reaction with eosino-
philia and systemic symptoms (DRESS), Churg-Strauss, a hema-
tologic malignancy – particularly a myeloproliferative or T-cell
lymphoproliferative disorder – or idiopathic hypereosinophilia.
A lymph node biopsy demonstrated reactive changes but
no evidence of malignancy. Bone marrow aspirate showed
hypereosinophilia but no atypia. FISH analysis for the FIPIlI/
PDGFRA fusion gene was negative, and no clonal T-cell recep-
tor gene rearrangements were detected. Subsequent peripheral
blood flow cytometry revealed clonal B-cell proliferation sugges-
tive of a low-grade B-cell lymphoma.
The patient was diagnosed with hypereosinophilia sec-
ondary to a low-grade B-cell lymphoma. High-dose systemic
steroids were commenced with resolution of the patient’s cuta-
neous and systemic symptoms. Attempts to wean steroid ther-
apy resulted in symptom recurrence (Fig. 1).
The monoclonal antibody rituximab was administered
(375 mg/m2 once weekly) for a 4-week period to target the clo-
nal B-cell population driving the hypereosinophilia. Subsequently
steroids were successfully weaned, the rash resolved, and eosi-
nophil count was normalized. Radiological follow-up at 1 year
confirmed the absence of lymphadenopathy and splenomegaly.
Follow-up includes 6-month review with full blood counts. Five
years later, he remains asymptomatic.
Hypereosinophilia is a complex multisystem condition.
Lymphoproliferative hypereosinophilia is usually driven by T-cell
malignancies, but cases have been described in relation to B-
cell non-Hodgkin’s lymphoma.7 This case is unusual because
the hypereosinophilia was driven by a low-grade B-cell lym-
phoma and demonstrates the importance of hematological input
and blood flow or bone marrow cytometry in patients with hyper-
eosinophilia.
Prolonged hypereosinophilia causes tissue damage. Early
diagnosis and treatment are vital to limit end-organ damage and
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